Cargando…

Correction to: Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO

Detalles Bibliográficos
Autores principales:	Regnault, Antoine, Morel, Thomas, de la Loge, Christine, Mazerolle, Flora, Kaminski, Henry J., Habib, Ali A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444721/ https://www.ncbi.nlm.nih.gov/pubmed/37368226 http://dx.doi.org/10.1007/s40120-023-00508-2

Ejemplares similares

Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO
por: Regnault, Antoine, et al.
Publicado: (2023)

Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease
por: Cleanthous, Sophie, et al.
Publicado: (2021)

Myasthenia gravis: MuSK MG, late-onset MG and ocular MG
por: Deymeer, Feza
Publicado: (2020)

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)
por: Muppidi, Srikanth, et al.
Publicado: (2020)

Sensitivity of MG‐ADL for generalized weakness in myasthenia gravis
por: de Meel, R. H. P., et al.
Publicado: (2018)

Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management
por: Lazaridis, Konstantinos, et al.
Publicado: (2020)

MyastheniaGravis(MG) in a patient with Juvenile Idiopathic Arthritis
por: Scott, Christiaan, et al.
Publicado: (2011)

Quality of Life in Myasthenia Gravis and Correlation of MG-QOL15 with Other Functional Scales
por: Diez Porras, Laura, et al.
Publicado: (2022)

Utilization of MG‐ADL in myasthenia gravis clinical research and care [Image: see text]
por: Muppidi, Srikanth, et al.
Publicado: (2022)

Corticosteroid Treatment-Resistance in Myasthenia Gravis
por: Kaminski, Henry J., et al.
Publicado: (2022)

Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020)

Prognostic Analysis of Thymoma-Associated Myasthenia Gravis (MG) in Chinese Patients and Its Implication of MG Management: Experiences from a Tertiary Hospital
por: Chen, Di, et al.
Publicado: (2020)

Fatigue in myasthenia gravis: is it more than muscular weakness?
por: Elsais, Ahmed, et al.
Publicado: (2013)

Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study
por: McPherson, Tarrant, et al.
Publicado: (2020)

Botulinum toxin injections associated with suspected myasthenia gravis: An underappreciated cause of MG-like clinical presentation
por: Punga, Anna Rostedt, et al.
Publicado: (2020)

Prevalence of depression and anxiety among myasthenia gravis (MG) patients: A systematic review and meta‐analysis
por: Nadali, Javad, et al.
Publicado: (2022)

Association between COVID‐19 and myasthenia gravis (MG): A genetic correlation and Mendelian randomization study
por: Sun, Dongren, et al.
Publicado: (2023)

Monoclonal Antibody-Based Therapies for Myasthenia Gravis
por: Alabbad, Sawsan, et al.
Publicado: (2020)

Grave Prognosis of the MuscleSpecific Kinase (MuSK)-positive Myasthenia Gravis (MG): A False Prejudice
por: Hiew, Fu Liong
Publicado: (2020)

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic
por: Jacob, Saiju, et al.
Publicado: (2020)

Percutaneous Electrical Nerve Stimulation (PENS) for Infrapatellar Saphenous Neuralgia Management in a Patient with Myasthenia gravis (MG)
por: Martín Pérez, Sebastián Eustaquio, et al.
Publicado: (2023)

Serum metabolomics of treatment response in myasthenia gravis
por: Sikorski, Patricia, et al.
Publicado: (2023)

Thymoma Associated Myasthenia Gravis (TAMG): Differential Expression of Functional Pathways in Relation to MG Status in Different Thymoma Histotypes
por: Yamada, Yosuke, et al.
Publicado: (2020)

One‐year follow‐up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry
por: Lee, Ikjae, et al.
Publicado: (2022)

Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Myasthenia Gravis
Publicado: (1905)

Myasthenia Gravis
por: Wilson, Andrew
Publicado: (1952)

Myasthenia Gravis
por: Bramwell, Edwin
Publicado: (1901)

Lower Urinary Tract Symptoms in Myasthenia Gravis
por: Tateno, Fuyuki, et al.
Publicado: (2021)

Galcanezumab-Induced Myasthenia Gravis-Like Symptoms
por: Mubaraki, Adnan A
Publicado: (2023)

Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials
por: Guptill, Jeffrey T., et al.
Publicado: (2023)

Patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG)
por: Berrih-Aknin, Sonia, et al.
Publicado: (2021)

Association Between Myasthenia Gravis–Activities of Daily Living (MG-ADL) and EQ-5D-5L Utility Values: The Additional Effect of Efgartigimod on Utilities
por: Dewilde, Sarah, et al.
Publicado: (2023)

Serum Metabolomic Response of Myasthenia Gravis Patients to Chronic Prednisone Treatment
por: Sengupta, Manjistha, et al.
Publicado: (2014)

Clinical characteristics of myasthenia gravis (MG) patients developing other autoimmune diseases after thymectomy from one single center cohort
por: Tian, Wenxin, et al.
Publicado: (2022)

Thymectomy for myasthenia gravis
por: Moorehead, R J, et al.
Publicado: (1985)

Thymectomy in Myasthenia Gravis
por: Dunlop, D. M.
Publicado: (1953)

Thymectomy in Myasthenia Gravis
por: Brown, K. Paterson
Publicado: (1953)

Thymectomy for Myasthenia Gravis
por: Keynes, Geoffrey
Publicado: (1949)

Cannot write session to /tmp/vufind_sessions/sess_t0g94e4g3acas53mlbkncoi7kk